|Awarded On||February 16, 2022|
|Title||i-SINFOP: Integrative Systems-scale Interrogation of Neomorphic Fusion OncoProteins|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Nidhi Sahni|
|Cancer Sites||All Sites|
Gene fusions, encoding fusion oncoproteins, represent an important class of oncogenic driver aberrations which hold great promise clinically for cancer therapy. A great success of personalized cancer therapy is the case of BCR-ABL fusion oncoprotein and the use of gleevec (imatinib) or related compounds. Apart from a few classic examples heavily investigated for decades, the remaining cancer gene fusions have negligible information about their functional consequences. These examples argue that, understanding how gene fusions cause cancer will require parallel systematic platforms characterizing the molecular and mechanistic behaviors of fusion oncoproteins.
To tackle this problem, we propose...